Shareholder rights firm calls GeneDx Holdings investors to lead WGS securities fraud class action

Securities fraud class actions have become a consistent feature of the broader biotech listing cycle, and GeneDx Holdings Corp. is now among those facing one. The Schall Law Firm, a national shareholder rights litigation firm based in Los Angeles, reminded investors on July 7, 2026, that a class action against GeneDx Holdings (NASDAQ: WGS) is active, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act.

The suit and its statutory basis

The Schall Law Firm's notice cited Sections 10(b) and 20(a) of the Securities Exchange Act as the legal framework for the lawsuit against GeneDx Holdings. The July 7 announcement did not include the specific conduct attributed to the company, the class period covered by the litigation, or any figure for claimed investor losses.

The firm described itself as a national shareholder rights litigation firm. Its July 7 release was distributed by PRNewswire. Short of those details, the notice offered little further characterization of the underlying allegations.

What WGS investors can do

GeneDx Holdings trades on the Nasdaq under the ticker WGS. The Schall Law Firm's announcement is directed at investors who held positions in the company and may wish to seek designation as lead plaintiff in the class action proceedings. No deadline for such applications appeared in the July 7 release.